Free Trial
NYSE:JNJ

Johnson & Johnson (JNJ) Stock Price, News & Analysis

$165.52
+0.88 (+0.53%)
(As of 09/13/2024 ET)
Today's Range
$163.82
$165.75
50-Day Range
$145.48
$167.38
52-Week Range
$143.13
$168.85
Volume
3.69 million shs
Average Volume
7.20 million shs
Market Capitalization
$398.45 billion
P/E Ratio
10.32
Dividend Yield
3.00%
Price Target
$173.21

Johnson & Johnson MarketRank™ Stock Analysis

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
4.6% Upside
$173.21 Price Target
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.50mentions of Johnson & Johnson in the last 14 days
Based on 41 Articles This Week
Insider Trading
Selling Shares
$930,113 Sold Last Quarter
Proj. Earnings Growth
5.99%
From $10.02 to $10.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

77th out of 919 stocks

Pharmaceutical Preparations Industry

27th out of 425 stocks

JNJ stock logo

About Johnson & Johnson Stock (NYSE:JNJ)

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





JNJ Stock Price History

JNJ Stock News Headlines

Mikayla Brown and her husband, Tyler, visit the grave of their son, Elijah, who died of a fentanyl …
Dealers' paradise? How social media became a storefront for deadly fake pills as families struggle
Fentanyl overdoses have become a leading cause of death for minors in the last 5 years or so — and social media, where tainted, fake prescription drugs can be obtained with just a few clicks, is part of the problem
Image of bank notes rolled around plants on soil for business, saving, growth, economic concept — Photo
3 Safe Stocks with Safe Dividends for Your Portfolio (JNJ)
Secure your portfolio with stocks known for their stability and reliable dividend payouts, offering a sense of security during uncertain times.
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Johnson & Johnson (NYSE:JNJ) VP Sells $930,113.10 in Stock
Procter Gamble Company, PG official website homepage under magnifying glass.
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt (JNJ)
Shield your investments from market volatility with these four resilient defensive stocks, offering stability and potential growth despite uncertainty.
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Wells Fargo Sticks to Its Hold Rating for Johnson & Johnson (JNJ)
See More Headlines
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/17/2024
Ex-Dividend for 9/10 Dividend
8/27/2024
Dividend Payable
9/10/2024
Today
9/15/2024
Next Earnings (Confirmed)
10/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
47816010
Employees
131,900
Year Founded
1886

Price Target and Rating

Average Stock Price Target
$173.21
High Stock Price Target
$215.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+4.6%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$35.15 billion
Pretax Margin
22.53%

Debt

Sales & Book Value

Annual Sales
$85.16 billion
Cash Flow
$13.72 per share
Book Value
$28.57 per share

Miscellaneous

Outstanding Shares
2,407,240,000
Free Float
2,402,828,000
Market Cap
$398.45 billion
Optionable
Optionable
Beta
0.53

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • Johnson & Johnson's stock price has been relatively stable, providing a sense of security for investors.
  • Strong institutional investor interest in Johnson & Johnson indicates confidence in the company's performance and potential growth.
  • Recent insider selling activity could be seen as a positive sign, as it may indicate that insiders believe the stock is currently overvalued.
  • Analysts' price targets for Johnson & Johnson suggest potential upside, providing an opportunity for capital appreciation.
  • Johnson & Johnson's diverse product portfolio across pharmaceuticals, medical devices, and consumer health offers stability and resilience in various market conditions.

Cons

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Recent decrease in institutional holdings may raise concerns about the company's future performance and growth prospects.
  • Analysts' revised price targets downwards could indicate potential challenges or headwinds facing Johnson & Johnson in the near term.
  • Insider selling activity, such as the recent sale by VP Robert J. Decker, may signal lack of confidence in the company's future prospects.
  • Johnson & Johnson's debt-to-equity ratio of 0.44 may be a concern for investors as higher debt levels can increase financial risk.
  • Market analysts' mixed ratings on the stock, with some suggesting a hold position, may indicate uncertainty about the company's future performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 10, 2024. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

JNJ Stock Analysis - Frequently Asked Questions

How have JNJ shares performed this year?

Johnson & Johnson's stock was trading at $156.74 at the beginning of 2024. Since then, JNJ stock has increased by 5.6% and is now trading at $165.52.
View the best growth stocks for 2024 here
.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings results on Wednesday, July, 17th. The company reported $2.82 earnings per share for the quarter, beating analysts' consensus estimates of $2.71 by $0.11. The company's revenue for the quarter was up 4.3% on a year-over-year basis.
Read the conference call transcript
.

Does Johnson & Johnson have any subsidiaries?

The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's top institutional shareholders include Legal & General Group Plc (0.97%), Bank of New York Mellon Corp (0.90%), Massachusetts Financial Services Co. MA (0.78%) and Ameriprise Financial Inc. (0.60%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker and James D Swanson.
View institutional ownership trends
.

How do I buy shares of Johnson & Johnson?

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC) and JPMorgan Chase & Co. (JPM).

This page (NYSE:JNJ) was last updated on 9/15/2024 by MarketBeat.com Staff

From Our Partners